ALLMedicine™ Cold Agglutinin Disease Center
Research & Reviews 99 results
BMJ Case Reports; Ahmed Y, Khandelwal A et. al.
Jul 28th, 2021 - A 70-year-old man with known cold autoimmune haemolytic anaemia was referred to the emergency department with increased shortness of breath on exertion. He had been confirmed positive for non-variant COVID-19 infection 1 week earlier based on naso...
Current Medical Research and Opinion; Vágó EK, Nicholson G et. al.
Jul 27th, 2021 - Cold agglutinin disease (CAD) is a rare form of autoimmune hemolytic anemia that may manifest in complement-mediated chronic hemolytic anemia, profound fatigue, and transient agglutination-mediated circulatory symptoms. This study compared the hea...
Blood Jalink M, Berentsen S et. al.
Jul 23rd, 2021 - Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome.|2021|Jalink M,Berentsen S,Castillo JJ,Treon SP,Cruijsen M,|
Journal of Clinical Laboratory Analysis; Ying Q, Lv D et. al.
Jul 4th, 2021 - Autoimmune hemolytic anemia (AIHA) is a rare disease characterized by hemolysis caused by autoantibodies against erythrocyte surface antigen. These antibodies can be classified as warm, cold, or mixed types. We report two cases of cold agglutinin ...
Clinicaltrials.gov 6 results
Apr 24th, 2020 - The purpose of Part A is to determine whether sutimlimab administration results in a greater than or equal to (>=) 2 gram per deciliter (g/dL) increase in hemoglobin (Hgb) levels or increases Hgb to >= 12 g/dL and obviates the need for blood trans...
Apr 24th, 2020 - The purpose of Part A is to determine whether sutimlimab administration results in a greater than or equal to (>=)1.5 gram per deciliter (g/dL) increase in hemoglobin (Hgb) level and avoidance of transfusion in participants with primary cold agglu...
Feb 7th, 2020 - This study is to assess the safety, tolerability, preliminary efficacy, and pharmacokinetics of APL-2 in subjects with warm Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD).
Jul 19th, 2017 - Evaluation of the efficacy and safety of eculizumab in symptomatic or transfusion-dependent patients with untreated or refractory hemolytic cold agglutinin disease(CAD)
Jan 9th, 2017 - Prospective, non-randomized multicenter study on the safety and efficacy of combination therapy with bendamustine and rituximab for chronic cold agglutinin disease.
News 7 results
May 14th, 2020 - FILE PHOTO: The logo of Sanofi is seen at the company's headquarters in Paris, France, April 24, 2020. REUTERS/Charles Platiau PARIS (Reuters) - French healthcare company Sanofi said on Thursday that the U.S. Food & Drug Administration (FDA) regul...
Dec 12th, 2019 - ORLANDO – An investigational selective inhibitor of the complement pathway, sutimlimab, induced rapid and sustained benefits in patients with cold agglutinin disease, a rare autoimmune hemolytic anemia with no currently approved effective therapie.
Jan 2nd, 2019 - Red blood cells In a first-in-human trial, sutimlimab rapidly halted hemolysis, corrected anemia, precluded the need for transfusion, and caused no serious adverse effects in patients with cold agglutinin disease. Sutimlimab also “induced clinical.
Mar 28th, 2018 - Action Points Scalp cooling was a safe, effective, and well-tolerated method for preventing chemotherapy-induced alopecia. The analysis showed that scalp cooling is significantly more effective with taxane-based compared to anthracycline-based che...
Mar 2nd, 2016 - The median survival for Waldenström macroglobulinemia ranges from 5 to 10 years. In certain patient populations, the disease can be more aggressive. The five adverse covariates that have been identified by the International Prognostic Scorin...